Background:Most congenital heart diseases(CHDs)have specific hemodynamics,including volume and pressure overload,as well as cyanosis and pulmonary hypertension,associated with anatomical abnormalities.Such hemodynamic...Background:Most congenital heart diseases(CHDs)have specific hemodynamics,including volume and pressure overload,as well as cyanosis and pulmonary hypertension,associated with anatomical abnormalities.Such hemodynamic abnormalities can cause activation of neurohormones,inflammatory cytokines,fibroblasts,and vascular endothelial cells,which in turn contribute to the development of pathologic conditions such as cardiac hypertrophy,fi brosis,and cardiac cell damages and death.Measuring biomarker levels facilitates the prediction of these pathological changes,and provides information about the stress placed on the myocardial cells,the severity of the damage,the responses of neurohumoral factors,and the remodeling of the ventricle.Compared to the ample information on cardiac biomarkers in adult heart diseases,data from children with CHD are still limited.Data sources:We reviewed cardiac biomarkers-specifi cally focusing on troponin as a biomarker of myocardial damage,amino-terminal procollagen type III peptide(PIIIP)as a biomarker of myocardialfi brosis and stromal remodeling,and B-type natriuretic peptide(BNP)/N-terminal proBNP as biomarkers of cardiac load and heart failure,by introducing relevant publications,including our own,on pediatric CHD patients as well as adults.Results:Levels of highly sensitive troponin I are elevated in patients with atrial septal defects(ASDs)and ventricular septal defects(VSDs).PIIIP levels are also elevated in patients with ASD,VSD,pulmonary stenosis,and Tetralogy of Fallot.Measurement of BNP and N-terminal proBNP levels shows good correlation with heart failure score in children.Conclusions:In the treatment of children with CHD requiring delicate care,it is vital to know the specifi c degree of myocardial damage and severity of heart failure.Cardiac biomarkers are useful tools for ascertaining the condition of CHDs with ease and are likely to be useful in determining the appropriate care of pediatric cardiology patients.展开更多
文摘Background:Most congenital heart diseases(CHDs)have specific hemodynamics,including volume and pressure overload,as well as cyanosis and pulmonary hypertension,associated with anatomical abnormalities.Such hemodynamic abnormalities can cause activation of neurohormones,inflammatory cytokines,fibroblasts,and vascular endothelial cells,which in turn contribute to the development of pathologic conditions such as cardiac hypertrophy,fi brosis,and cardiac cell damages and death.Measuring biomarker levels facilitates the prediction of these pathological changes,and provides information about the stress placed on the myocardial cells,the severity of the damage,the responses of neurohumoral factors,and the remodeling of the ventricle.Compared to the ample information on cardiac biomarkers in adult heart diseases,data from children with CHD are still limited.Data sources:We reviewed cardiac biomarkers-specifi cally focusing on troponin as a biomarker of myocardial damage,amino-terminal procollagen type III peptide(PIIIP)as a biomarker of myocardialfi brosis and stromal remodeling,and B-type natriuretic peptide(BNP)/N-terminal proBNP as biomarkers of cardiac load and heart failure,by introducing relevant publications,including our own,on pediatric CHD patients as well as adults.Results:Levels of highly sensitive troponin I are elevated in patients with atrial septal defects(ASDs)and ventricular septal defects(VSDs).PIIIP levels are also elevated in patients with ASD,VSD,pulmonary stenosis,and Tetralogy of Fallot.Measurement of BNP and N-terminal proBNP levels shows good correlation with heart failure score in children.Conclusions:In the treatment of children with CHD requiring delicate care,it is vital to know the specifi c degree of myocardial damage and severity of heart failure.Cardiac biomarkers are useful tools for ascertaining the condition of CHDs with ease and are likely to be useful in determining the appropriate care of pediatric cardiology patients.
